Effect of Gelesis200 on Body Weight in Overweight and Obese Subjects w/o Type 2 Diabetes (LIGHT-UP)

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Assessing the Effect of Gelesis200 on Body Weight in Overweight and Obese Subjects Without or With Type 2 Diabetes

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Assessing the Effect of Gelesis200 on Body Weight in Overweight and Obese Subjects without or with Type 2 Diabetes

Study Overview

• Status: Unknown
• Conditions: Obesity; Diabetes; Overweight; PreDiabetes
• Intervention / Treatment: Device: Gelesis200; Device: Placebo

Detailed Description

Multicenter, two-cohort, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose, adaptive (Two Phases).

In the first Phase of the adaptive design, unblinded interim analyses were conducted on 57 subjects and used to adjust the design for the second Phase. The first Phase was completed under protocol Version 1.0. Data used in the unblinded interim analyses of the first Phase will not be included in the second Phase (protocol Version 2.0 and subsequent protocol versions) analyses.

The study will evaluate the safety, tolerability and efficacy of Gelesis200 as a superabsorbent hydrogel for weight loss in treated diabetic subjects, untreated diabetic subjects, and prediabetic subjects (Cohort 1).

The study will evaluate separately the safety, tolerability and efficacy of Gelesis200 for weight loss in normoglycemic subjects (Cohort 2).

• Study Type: Interventional
• Enrollment (Anticipated): 300
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Canada
  • Ontario
    • Ottawa, Ontario, Canada, K1N 6N5
      • University of Ottawa - Institut de Recherche de l'Hospital d'Ottawa (IRHO) (Ottawa Hospital Research Institute (OHRI))
  • Quebec
    • Quebec City, Quebec, Canada, G1V 0A6
      • Université Laval
• Czechia
  • Prague, Czechia, 182 00
    • Health&Care, s.r.o
• Denmark
  • Frederiksberg, Denmark, 1958
    • University of Copenhagen - Department of Nutrition, Exercise and Sports
• Hungary
  • Budapest, Hungary, 1036
    • Qualiclinic Kft
  • Debrecen, Hungary, H-4032
    • Debreceni Egyetem Klinikai Kozpont
  • Gyula, Hungary, 5701
    • Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaz
• Italy
  • San Donato Milanese, Italy, 20097
    • IRCCS Policlinico San Donato
• Poland
  • Bialystok, Poland, 15-435
    • NZOZ Specjalistyczny Osrodek Internistyczno - Diabetologiczny
  • Lodz, Poland, 94-048
    • NZOZ All - Med Centrum Medyczne Specjalistyczne Gabinety Lekarskie Marcin Ogorek
  • Oswiecim, Poland, 32-600
    • Medicome Sp. Z O.O.
  • Poznan, Poland, 60-589
    • Centrum Zdrowia Metabolicznego Pawel Bogdanski
  • Warszawa, Poland, 02-679
    • Centrum Badawcze Wspolczesnej Terapii
• United Kingdom
  • Blackburn, United Kingdom, BB21AX
    • Oakenhurst Medical Practice
  • Chesterfield, United Kingdom, v
    • Ashgate Medical Practice (Research Office)
  • Liverpool, United Kingdom, L9 7AL
    • Aintree University Hospital
  • Middlesbrough, United Kingdom, TS4 3 BW
    • The James Cook University Hospital
  • Swansea, United Kingdom, SA6 6NL
    • Morriston Hospital
• United States
  • Alabama
    • Birmingham, Alabama, United States, 35209
      • Central Alabama Research
  • Florida
    • Bradenton, Florida, United States, 34201
      • Meridien Research, Inc - Bradenton
    • Miami, Florida, United States, 33156
      • Baptist Diabetes Associates, P.A.
    • West Palm Beach, Florida, United States, 33401
      • Metabolic Research Institute, Inc.
  • Kansas
    • Kansas City, Kansas, United States, 64114
      • The Center for Pharmaceutical Research
  • Nevada
    • Las Vegas, Nevada, United States, 89104
      • Clinical Research Center of Nevada
  • Ohio
    • Cincinnati, Ohio, United States, 45236
      • Radiant Research
  • South Carolina
    • Greer, South Carolina, United States, 29651
      • Mountain View CLinical Research - Greer
  • Tennessee
    • Knoxville, Tennessee, United States, 37920
      • Volunteer Research Group and New Orleans Center for Clinical Research - Knoxville
  • Texas
    • San Antonio, Texas, United States, 78229
      • SAMCRC
    • Sugar Land, Texas, United States, 77478
      • Tarheel Clinical Research, LLC
  • Washington
    • Renton, Washington, United States, 98057
      • Rainier Clinical Research Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 22 years to 65 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Male or female
2. Age ≥22 years and ≤65 years
3. Ambulatory
4. BMI ≥27 kg/M2 and ≤40 kg/M2

5. Non-diabetic subjects, including:

   1. Normoglycemic subjects with FPG <100 mg/dL [<5.6 mmol/L] at both Screening Visits with HbA1c <5.7% (<39 mmol/mol), or
   2. Prediabetic subjects with FPG ≥100 mg/dL and <126 mg/dL (≥5.6 mmol/L and ≤7.0 mmol/L) at both Screening Visits with HbA1c ≤6.4% (≤46 mmol/mol) [if only one (1) value is within this range, the other value should not be ≥126 mg/dL (≥7.0 mmol/L) and HbA1c should be ≥5.7% (≥39 mmol/mol) and ≤6.4% (≤46 mmol/mol)]; or Diabetic subjects, including:
   1. Untreated subjects with FPG ≤200 mg/dL (≤11.2 mmol/L) at both Screening Visits and either FPG ≥126 mg/dL (≥7.0 mmol/L) at both Screening Visits or FPG <126 mg/dL (<7.0 mmol/L) at one (1) or both Screening Visits with HbA1c ≥6.5% (≥48 mmol/mol), or
   2. Drug-treated subjects with metformin and/or DPP-4 inhibitors with FPG ≥70 mg/dL and ≤270 mg/dL (≥3.9 mmol/L and ≤15.1 mmol/L) at both Screening Visits
6. Ability to follow verbal and written instructions
7. Consent obtained via signed ICF

Exclusion Criteria:

1. Pregnancy (or positive serum or urine pregnancy test(s) in females of childbearing potential)
2. Absence of medically approved contraception in females of childbearing potential (e.g., hysterectomy, oral contraceptive medications, intrauterine device combined with a barrier method, two (2) combined barrier methods such as diaphragm and condom or spermicide, or condom and spermicide; bilateral tubal ligation and vasectomy are acceptable contraceptive methods when combined with a single method above)
3. History of allergic reaction to CMC, citric acid, sodium stearyl fumarate, maltodextrin, gelatin, or titanium dioxide
4. Participation in a weight loss study within the past six (6) months
5. Administration of GSP2, GSP3, Gelesis100, or Gelesis200 in a previous study
6. Administration of investigational products within one (1) month prior to Screening Visit 1
7. Blood transfusion within three (3) months prior to Screening Visit 1
8. Smoking cessation within six (6) months prior to Screening Visit 1 or considering smoking cessation during the study
9. Anticipated surgical intervention during the study period
10. Known Type 1 Diabetes
11. History of eating disorders including binge eating (except mild binge eating) or emesis ≥2/week from any cause within six (6) months prior to Screening Visit 1
12. Weight change ≥3% within three (3) months prior to and during the Screening period
13. Supine SBP >160 mm Hg and/or supine DBP >95 mm Hg
14. Angina, coronary bypass, or myocardial infarction within six (6) months prior to Screening Visit 1
15. History of swallowing disorders within six (6) months prior to Screening Visit 1
16. Esophageal anatomic abnormalities (e.g., webs, diverticuli, rings)
17. History of gastric or duodenal ulcer within six (6) months prior to Screening Visit 1
18. History of gastroparesis (e.g., chronic nausea, vomiting ≥2 occurrences per week, heartburn, etc.) within six (6) months prior to Screening Visit 1
19. History of gastric bypass or any other gastric surgery
20. History of inflammatory bowel diseases
21. History of intestinal stricture (e.g., Crohn's disease)
22. History of intestinal obstruction or high risk of intestinal obstruction, including suspected small bowel adhesions
23. History of pancreatitis within six (6) months prior to Screening Visit 1
24. History of malabsorption within six (6) months prior to Screening Visit 1
25. Laxative users, except those on stable doses within one (1) month prior to Screening Visit 1
26. History of hepatitis B or C within six (6) months prior to Screening Visit 1
27. History of HIV
28. History of cancer within the past five (5) years (except adequately-treated localized basal cell skin cancer or in situ uterine cervical cancer)
29. Any other clinically significant disease interfering with the assessments of Gelesis200 (e.g., disease requiring corrective treatment, potentially leading to study discontinuation)
30. Abnormal serum TSH
31. HbA1c >8.5% (>69 mmol/mol)
32. Serum LDL cholesterol ≥160 mg/dL (≥4.15 mmol/L)
33. Serum triglycerides ≥350 mg/dL (≥3.96 mmol/L)
34. Positive test for drugs of abuse in the urine
35. Any relevant biochemical abnormality interfering with the assessments of Gelesis200
36. Anti-obesity medications (including herbal preparations) within one (1) month prior to Screening Visit 1
37. Systemic corticosteroids within one (1) month prior to Screening Visit 1
38. Thyroid hormones or preparations within one (1) month prior to Screening Visit 1 [except stable dose of replacement therapy for at least two (2) months]
39. TSH suppression therapy for thyroid cancer
40. Estrogen within one (1) month prior to Screening Visit 1 [except stable dose of replacement therapy or contraceptives for at least one (1) month]
41. Any other medication known to cause weight loss or weight gain within one (1) month prior to Screening Visit 1
42. Antidiabetic medications within one (1) month prior to Screening Visit 1 [except stable doses of metformin and DPP-4 inhibitors for at least one (1) month in subjects with Type 2 Diabetes]
43. Change in medications treating hypertension within one (1) month [one (1) week for diuretics] prior to Screening Visit 1
44. Change in medications treating dyslipidemia within one (1) month prior to Screening Visit 1
45. Anticipated requirement for use of prohibited concomitant medications
46. Any other condition that, in the opinion of the Investigator or Sponsor, would interfere with the subject's ability to participate in the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: TRIPLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Gelesis200; Gelesis200: Three (3) Gelesis200 capsules (2.10 gram (g)) two (2) times per day (id est (i.e.), lunch and dinner)	Device: Gelesis200; Subject would take Gelesis200 capsules 2 times per day.
PLACEBO_COMPARATOR: Placebo; Placebo: Three (3) placebo capsules two (2) times per day (i.e., lunch and dinner)	Device: Placebo; Subject would take placebo capsules 2 times per day.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of subjects with weight loss ≥5.0%	In treated diabetic subjects, untreated diabetic subjects, and pre-diabetic subjects (Cohort 1)	Change from baseline to day 171 (week 25)
Percent change in body weight	In treated diabetic subjects, untreated diabetic subjects, and pre-diabetic subjects (Cohort 1)	Change from baseline to day 171 (week 25)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of subjects with weight loss ≥10.0%	In treated diabetic subjects, untreated diabetic subjects, and pre-diabetic subjects (Cohort 1)	Up to 25 weeks
Proportion of subjects with weight loss ≥10.0%	Treated diabetics (subgroup of Cohort 1)	Up to 25 weeks
Proportion of subjects with weight loss ≥10.0%	Pre-diabetics and untreated diabetics (subgroup of Cohort 1)	Up to 25 weeks
Proportion of subjects with weight loss ≥5.0%	Treated diabetic subjects (subgroup of Cohort 1)	Up to 25 weeks
Proportion of subjects with weight loss ≥5.0%	Pre-diabetics and untreated diabetics (subgroup of Cohort 1)	Up to 25 weeks
Percent change in FSI	Pre-diabetics and untreated diabetics (subgroup of Cohort 1)	Up to 25 weeks
Percent change in insulin AUC during OGTT	Pre-diabetic subjects (subgroup of Cohort 1)	Up to 25 weeks
Change in HbA1c	Diabetic subjects with HbA1c ≥7.5% (≥58 mmol/mol) at baseline (subgroup of Cohort 1)	Up to 25 weeks

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of subjects with weight loss ≥7.5%	In treated diabetic subjects, untreated diabetic subjects, and pre-diabetic subjects (Cohort 1)	Change from baseline to day 171 (week 25)
Proportion of subjects with weight loss ≥7.5%	In treated diabetic subjects (subgroup of Cohort 1)	Change from baseline to day 171 (week 25)
Proportion of subjects with weight loss ≥7.5%	Pre-diabetics and untreated diabetics (subgroup of Cohort 1)	Change from baseline to day 171 (week 25)
Percent change in body weight	In treated diabetic subjects (subgroup of Cohort 1)	Change from baseline to day 171 (week 25)
Percent change in body weight	Pre-diabetics and untreated diabetics (subgroup of Cohort 1)	Change from baseline to day 171 (week 25)
Change in waist circumference	In treated diabetic subjects, untreated diabetic subjects, and pre-diabetic subjects (Cohort 1)	Change from baseline to day 171 (week 25)
Percent change in estimated excess body weight	In treated diabetic subjects, untreated diabetic subjects, and pre-diabetic subjects (Cohort 1)	Change from baseline to day 171 (week 25)
Change in BMI	In treated diabetic subjects, untreated diabetic subjects, and pre-diabetic subjects (Cohort 1)	Change from baseline to day 171 (week 25)
Percent change in FSI	In subjects FSI ≥10 µU/mL in both screening visits (subgroup of Cohort 1)	Change from baseline to day 171 (week 25)
Percent change in HOMA-IR and log HOMA-IR	Pre-diabetics and untreated diabetics (subgroup of Cohort 1)	Change from baseline to day 171 (week 25)
Percent change in QUICKI	Pre-diabetics and untreated diabetics (subgroup of Cohort 1)	Change from baseline to day 171 (week 25)
Percent change in fasting serum lipids	Subjects with dyslipidemia defined as LDL ≥130 mg/dL (≥3.37 mmol/L) and/or triglycerides ≥150 mg/dL (≥1.69 mmol/L)] at baseline (subgroup of Cohort 1)	Change from baseline to day 171 (week 25)
Change in blood pressure	Subjects with hypertension defined as SBP ≥140 mm Hg and/or DBP ≥90 mm Hg) at baseline (subgroup of Cohort 1)	Change from baseline to day 171 (week 25)
Proportion of subjects with weight loss ≥5.0%	Normoglycemic subjects (Cohort 2)	Change from baseline to day 171 (week 25)
Percent change in body weight	Normoglycemic subjects (Cohort 2)	Change from baseline to day 171 (week 25)
Percent change in FSI	Subjects with FSI ≥10 µU/mL at both Screening Visits (subgroup of Cohort 2)	Change from baseline to day 171 (week 25)
Percent change in insulin AUC during OGTT	Subjects with FSI ≥10 µU/mL at both Screening Visits (subgroup of Cohort 2)	Change from baseline to day 171 (week 25)
Proportion of subjects with weight loss ≥7.5%	Normoglycemic subjects (Cohort 2)	Change from baseline to day 171 (week 25)

Collaborators and Investigators

• Sponsor: Gelesis, Inc.

Publications and helpful links

Helpful Links

• Gelesis Website

Study record dates

Study Major Dates

• Study Start (ACTUAL): February 22, 2017
• Primary Completion (ANTICIPATED): January 15, 2021
• Study Completion (ANTICIPATED): January 15, 2021

Study Registration Dates

• First Submitted: January 13, 2017
• First Submitted That Met QC Criteria: February 15, 2017
• First Posted (ACTUAL): February 20, 2017

Study Record Updates

• Last Update Posted (ACTUAL): July 21, 2020
• Last Update Submitted That Met QC Criteria: July 20, 2020
• Last Verified: July 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Diabetes Mellitus; Overweight; Body Weight
• Other Study ID Numbers: GS-200-002

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No